Lung Cancer Screening Improves Stage I Detection, Reduces Stage IV Cases
Implementing lung cancer screening at four diverse healthcare systems resulted in a 6.6% decrease in Stage IV disease.
Read MorePosted by Andy Lundin | Sep 7, 2022 | Lung Cancer |
Implementing lung cancer screening at four diverse healthcare systems resulted in a 6.6% decrease in Stage IV disease.
Read MorePosted by Chris Wolski | Sep 2, 2022 | Cancer, Molecular Diagnostics |
Exai Bio combines novel oncRNA technology with AI to develop next-generation liquid biopsy tests that will aid in the detection of cancer.
Read MorePosted by Andy Lundin | Aug 25, 2022 | Cardiovascular |
Researchers found that a novel blood test can be used to easily evaluate disease severity in patients with pulmonary arterial hypertension.
Read MorePosted by Andy Lundin | Aug 19, 2022 | Lung Cancer |
A new collaborative project has successfully demonstrated a superior ability to detect circulating tumor DNA (ctDNA) from saliva.
Read MorePosted by Andy Lundin | Aug 15, 2022 | Company News, Lung Cancer |
ENHERTU is a specifically engineered HER2 directed antibody drug conjugate developed and commercialized by Daiichi Sankyo and AstraZeneca.
Read More